Norelgestromin and Ethinyl Estradiol
Dosage form: patch
Drug class:Contraceptives
Medically reviewed by Drugs.com. Last updated on Mar 1, 2022.
On This Page
- Boxed Warning
- Indications and Usage
- Dosage and Administration
- Dosage Forms and Strengths
- Contraindications
- Warnings and Precautions
- Adverse Reactions/Side Effects
- Drug Interactions
- Use In Specific Populations
- Overdosage
- Description
- Clinical Pharmacology
- Nonclinical Toxicology
- Clinical Studies
- How Supplied/Storage and Handling
- Patient Counseling Information
- Cigarette Smoking and Serious Cardiovascular Events
Cigarette smoking increases the risk of serious cardiovascular events from hormonal contraceptive use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, CHCs, includingNorelgestromin and Ethinyl Estradiol transdermal system, are contraindicated in women who are over 35 years of age and smoke [see Contraindications (4)and Warnings and Precautions (5.1)].
- Contraindicated in Women with a BMI ≥ 30 kg/m2
Norelgestromin and Ethinyl Estradiol transdermal systemis contraindicated in women with a BMI ≥ 30 kg/m2. The risk of VTE may be greater withNorelgestromin and Ethinyl Estradiol transdermal systemin women with a BMI > 30 kg/m2 compared to women with a lower BMI[see Contraindications (4)and Warnings and Precautions (5.1)].
